Prostate cancer(PCa)is the second most common cancer in men with 17 million new cases in 2018 and 27 million new cases expected by 2040[1].Mortality is however declining which may reflect improvements in the treatment...Prostate cancer(PCa)is the second most common cancer in men with 17 million new cases in 2018 and 27 million new cases expected by 2040[1].Mortality is however declining which may reflect improvements in the treatments available[2].One such treatment is the robot-assisted laparoscopic prostatectomy(RALP)which was first performed in 2000 at the Department of Urology of Frankfurt University in Germany.Initial adoption was limited due to the lack of data supporting its safety and efficacy in terms of functional and oncological outcomes until the landmark studies published by Menon et al.[3,4].This paved the way for further studies such as the Swedish LAPRO trial.This revealed a moderate advantage for erectile dysfunction with RALP,compared to open radical retropubic prostatectomy(RRP),and no significant difference between the two in terms of cancer relapse at the 24-month follow-up[5].Consequently,the Da Vinci Robot is currently used worldwide,with an estimated 300000 urology procedures being performed in 2018[6].展开更多
文摘Prostate cancer(PCa)is the second most common cancer in men with 17 million new cases in 2018 and 27 million new cases expected by 2040[1].Mortality is however declining which may reflect improvements in the treatments available[2].One such treatment is the robot-assisted laparoscopic prostatectomy(RALP)which was first performed in 2000 at the Department of Urology of Frankfurt University in Germany.Initial adoption was limited due to the lack of data supporting its safety and efficacy in terms of functional and oncological outcomes until the landmark studies published by Menon et al.[3,4].This paved the way for further studies such as the Swedish LAPRO trial.This revealed a moderate advantage for erectile dysfunction with RALP,compared to open radical retropubic prostatectomy(RRP),and no significant difference between the two in terms of cancer relapse at the 24-month follow-up[5].Consequently,the Da Vinci Robot is currently used worldwide,with an estimated 300000 urology procedures being performed in 2018[6].
